CJC-1295 Without DAC Hormone Peptide Cjc-1295 with Dac for Fat Loss

Storage for CJC-1295 without DAC:
Lyophilized MOD GRF 1-29 is stable at room temperature for 90 days, however it should be stored in a freezer below -8°C for any extended period of time. After reconstitution, may be stored for a maximum of 14 days in a refrigerator at 2°C - 8°C. Store vials in an upright position. Store MOD GRF-129 refrigerated between temperatures 2°C - 8°C. Keep in the outer carton in order to protect from light. For one month can be stored at room temperature.

CJC-1295 without DAC usage:
Modified GRF 1-29 is also known as Mod GRF 1-29, but even more commonly known as CJC-1295 without DAC. It is a protein that is 29 amino acids long and it is a GHRH analogue. CJC-1295 without DAC acts on receptors at the pituitary gland to stimulate the release of Human Growth Hormone.

CJC-1295 without DAC could be referred to more properly as a second generation derivative of GHRH. GHRH is modified to create what is known as Releasing Factor (GRF) 1-29, also known as Sermorelin. GRF 1-29 is then further modified to create Mod GRF 1-29 which is CJC-1295 without DAC.

CJC-1295 without DAC Dosage:
Mod GRF 1-29 is typically provided in vials containing 2 mg of lyophylized powder, though the amount can vary. The contents should be reconstituted by adding a convenient amount of sterile or bacteriostatic water. If for example 2 mL is chosen and the dosing of the vial is 2 mg, the resulting solution then has a concentration of 1 mg/mL, or 1000 mcg/mL.

At time of dosing, an insulin syringe is used to draw and then inject the desired amount. In the above example, a 100 mcg dose would require a volume of 0.10 mL, or "10 IU" as marked on an insulin syringe.
Injection may be subcutaneous, intramuscular, or intravenous, according to personal preference. If desired, peptide solutions from other vials, such as a vial of a GHRP product, may also be drawn into the same syringe. This reduces the total number of injections required.

I ordinarily recommend a dosage of 100 mcg Mod GRF at a time, simultaneous with injection of a GHRP. For maximum effect, dosing is preferably three times per day at times of low blood sugar, for example about 30 minutes before a meal, but where use is ongoing, a common use is once per day prior to sleep.

Dosages and use of CJC-1295:
When recommending CJC 1295, I ordinarily recommend a dosage of 1000 mcg at a time, twice per week.
CJC 1295 is typically provided in vials containing 2 or 5 mg of lyophylized powder, though the amount can vary.

The contents should be reconstituted by adding a convenient amount of sterile or bacteriostatic water. If for example 2 mL is chosen and the dosing of the vial is 2 mg, the resulting solution then has a concentration of 1 mg/mL, or 1000 mcg/mL.

At time of dosing, an insulin syringe is used to draw and then inject the desired amount. In the above example, a 1000 mcg dose would require a volume of 1 mL, or "100 IU" as marked on an insulin syringe.
Injection may be subcutaneous, intramuscular, or intravenous according to personal preference.

If desired, peptide solutions from other vials, such as a vial of a GHRP product, may also be drawn into the same syringe, if there is room. This reduces the total number of injections required.

CJC-1295 DAC vs. CJC-1295 No DAC:

CJC-1295 DAC and CJC-1295 (also known as Modified GRF 1-29) are both Grow Hormone Releasing Hormones (GHRH). Their action in the human body is identical but the difference between the two peptides are the span of the half-life. Modified GRF 1-29 and Sermorelin have a very short acting half-life of about 30 minutes, while CJC-1295 DAC has a half-life that can last up to approximately 8 days. Many a scientist have reported that the short half-life of Sermorelin and Modified GRF 1-29 is considered to be much more natural as they produce a short pulse of Human Grow Hormone.

The Development of CJC-1295 DAC:

CJC-1295 DAC is a tetrasubstituted peptide analogue of Grow Hormone Releasing Hormones with D-Ala, Gln, Ala, and Leu substitutions at positions 2, 8, 15, and 27 respectively. A Canadian biotechnology company called ConjuChem had invented CJC-1295. Clinical Research on CJC-1295 first began during the mid-2000s. The goal of the peptide, acting to raise hgh likeIpamorelin, was to treat visceral fat deposits in obese AIDS patients because it is presumed that increased levels of exogenous hgH increase fat loss, or lipolysis. In one study, results showed that the measured GH release in rats over a two hour period showed that CJC-1295 released twice as much GH as CJC-1293 DAC. This result makes it preferable for immediate effectiveness as a result of the longer peak. With the use of a Grow Hormone Releasing Peptide (GHRP), such asGrow Hormone Releasing Hexapeptide (GHRP-6) in conjuction with CJC-1295 DAC, a study has shown that the GHRPs create a Grow Hormone pulse which helps the CJC-1295 work effectively. Clinical researchs involving CJC-1295 have shown that it had been successful for most research subjects.